Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06396871

Deep Phenotyping of Peripheral Blood Cells and Circulating Factors in Metabolic Diseases

The goal of this cross-sectional observational study is to to perform a thorough characterization of the quantitative and qualitative differences in peripheral blood cells, and circulating factors (proteins, metabolites, lipids, extracellular vesicles) in different stages of several metabolic diseases (diabetes, obesity, non-alcoholic fatty liver disease) that share common pathophysiological mechanisms and in comparison with adult healthy controls. The main question[s] it aims to answer are:

* Which are the quantitative (number and concentration) and qualtitative (characteristics, functional assays) differences in platelets in patients with metabolic diseases vs subjects without metabolic diseases * Which are the quantitative (number and concentration) and qualtitative (characteristics, functional assays) differences in leucocytes or circulating molecules in patients with metabolic diseases vs subjects without metabolic diseases

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > 18 years old

Additional inclusion criteria for case groups:

  • High risk group for significant liver fibrosis
  • FIB-4 score ≥ 1.3 AND 2. Fibroscan measurement ≥ 8kPa
  • Steatotic Liver Disease group
  • Diagnosis of steatosis in ultrasound AND CAP > 275 dB/m
  • Prediabetes
  • HbA1c >5.7 AND <6.5% OR/AND
  • Fasting Glucose 100-125 mg/dl OR/AND
  • Glucose at 120 min of OGTT between 140-200 mg/dl
  • Diabetes 1. HbA1c ≥ 6.5% OR/AND 2. Fasting Glucose > 126 mg/dl OR/AND 3. Glucose at 120 min of OGTT > 200 mg/dl

If a subject does not fulfil the additional criteria for participating in a case group, then he/she will be included in the respective control group which will be:

A#) Low risk for significant liver fibrosis 1. Fibroscan measurements < 8kPa B#) No steatosis group

  • No steatosis in liver ultrasound AND CAP ≤ 275 dB/m C#) Normal glucose tolerance test group
  • HbA1c < 5.7% AND
  • Fasting glucose < 100 mg/dl AND
  • Glucose at 120 min of OGTT <140 mg/dl

Exclusion criteria

  • Diabetes mellitus Typ 1
  • BMI < 18.5 kg/m2
  • Transfusion of blood or major bleeding in the last six months
  • Anaemia with haemoglobin < 9,0 g/dl
  • Chronic alcohol or drug abuse
  • Presence of any acute or chronic liver disease apart from non-alcoholic fatty liver disease (i.e. viral, autoimmune or alcoholic hepatitis, haemochromatosis, Morbus Wilson etc.)
  • Systemic infections (CRP > 1 mg/dl)
  • Medications that affect blood glucose levels (e.g. antidiabetics [except from the subjects forming the diabetes group], steroids) in the last six months
  • Medications that affect coagulation (e.g. anticoagulants and antiplatelet agents) in the last six months
  • Medications that affect immune function (e.g. immunosuppressive drugs) in the last six months
  • Pregnancy or breastfeeding
  • Severe psychic disorders
  • Inability to follow the study protocol
  • Have any medical condition unsuitable for inclusion in the study, in the opinion of the investigator

Additional exclusion criteria for MRI:

  • Pacemaker
  • Artificial heart valve
  • Metal prosthesis
  • Implanted magnetic metal parts
  • Spirals
  • Fixed metal dental braces
  • Acupuncture needle
  • Insulin pumps
  • By MRI > 3 Tesla: Tattoos, permanent eyeliner
  • Claustrophobia or any other condition, such as psychiatric disorder, that in the opinion of the investigator may prevent the participant from following and completing the protocol
  • Subject dimensions not allowing the performance of MRI

Treatment and study plan

Oral glucose tolerance test

Diagnostic Test

75g of a standardized glucose solution followed by blood draw at 0, 30, 60, 90, 120 min

Liver Ultrasound

Diagnostic Test

A crude assessment of liver status in order to identify the presence of steatosis or not will take place with ultrasound.

Fibroscan of the Liver

Diagnostic Test

FibroScan non-invasively measures the stiffness of the liver by capturing and calculating the speed of a shear wave as it travels through the liver (vibration controlled transient elastography).

Magentic Resonance Imaging (MRI) of the liver

Diagnostic Test

The exact calculation of liver fat with proton density fat fraction will take place with MRI.

Primary outcomes

  1. Qualitative differences in platelets

    Time frame: 1 day

    % of Platelet aggregation

  2. Quantitative differences in platelets

    Time frame: 1 day

    Platelet count in GPt/L

Secondary outcomes

  1. Quantitative differences in leukocytes

    Time frame: 1 day

    Leucocyte count in GPt/L

  2. Quantitative differences in neutrophils

    Time frame: 1 day

    Neutrophil count in GPt/L

  3. Quantitative differences in lymphocytes

    Time frame: 1 day

    Lymphocyte count in GPt/L

  4. Quantitative differences in monocytes

    Time frame: 1 day

    Monocyte count in GPt/L

  5. Qualitative differences in neutrophils in NETosis

    Time frame: 1 day

    % of neutrophils performing NETosis (FACS analysis)

  6. Qualitative differences in neutrophils in phagocytosis

    Time frame: 1 day

    % of neutrophils performing phagocytosis (FACS analysis)

  7. Qualitative differences in monocytes

    Time frame: 1 day

    % of monocytes performing phagocytosis (FACS analysis)

  8. Quantitative differences in Interleukin-6

    Time frame: 1 day

    Interleukin-6 in pg/ml

  9. Quantitative differences in Interleukin-8

    Time frame: 1 day

    Interleukin-8 in pg/ml

Study contacts

Contact information is provided by the study sponsor or research team.

Ingo Weigmann, MD

CONTACT

[email protected]

+4935145811723

Nikolaos Perakakis, MD

CONTACT

[email protected]

+4935145813651

Sponsors and collaborators

Lead sponsor

Technische Universität Dresden

Other

Registry information

Acronym: PERIMED

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
May 2, 2024
Registry last updated
May 2, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.